Clinical trials: Human Papillomavirus Vaccines
Human Papilloma Virus
Conversational Agents to Improve HPV Vaccine Acceptance in Primary Care (ECA-HPV)- Clinical Trial
The objective of this study is to assess the use of and satisfaction with the ECA-HPV intervention over a 16-month period, its ability to increase HPV vaccination, and the comparative effectiveness of clinic notification and…
- Trial name
- NCT06367699
- Testing
- Usual Care, ECA-HPV App with Clinic Notification and Adolescent Functions Disabled, ECA-HPV App with Clinic Notification Function Enabled
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Tufts Medical Center
Human Papillomavirus
A Phase I Clinical Trial of an HPV Therapeutic Vaccine
This study will consist of 300 women aged 18-50 years. The study will show that a new therapeutic human papillomavirus (HPV) vaccine designed to regress a precancerous condition called high-grade squamous intraepithelial…
- Trial name
- NCT01653249
- Testing
- Vaccine consisting of four HPV-16 E6 peptides in combination with Candin®
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- University of Arkansas
Head and Neck Cancer, Head and Neck Neoplasms
Anti-PD-L1/TGF-beta Trap (M7824) Alone and in Combination With TriAd Vaccine and N-803 for Resectable Head and Neck Squamous Cell Carcinoma Not Associated With Human Papillomavirus Infection
Background: Some people who get head and neck cancer will need surgery to treat their cancer. Research suggests that immunotherapy drugs may help fight head and neck cancer if given before surgery.
- Trial name
- NCT04247282
- Testing
- M7824, N803, TriAd vaccine
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Cervical Cancer, Human Papillomavirus Infection
Long Term Follow-up of HPV Vaccine in HIV (CTN 236)
The purpose of this extension study is to determine whether HPV antibody levels in HIV-positive girls and women will decline more rapidly and more significantly than in HIV-negative girls and women and if this decline is…
- Conditions
- Cervical Cancer, Human Papillomavirus Infection, Human Immunodeficiency Virus, Cervical Dysplasia
- Trial name
- NCT06915779
- Where
- 13 sites in Canada
- Volunteers
- 241 people
- Sponsor
- University of British Columbia
Cervical Cancer Prevention
Study on the Safety, Humoral Immune Response, and Memory B Cell Response Characteristics of Sequential 9-Valent HPV Vaccination
This is a single-center, prospective, open-label, partially randomized, matched-controlled trial designed as a cohort study. The study plans to enroll 360 healthy female participants aged 18 to 45 years, divided into three…
- Trial name
- NCT07530679
- Testing
- 9-valent HPV vaccination at months 0 and 6, 9-valent HPV vaccination at months 0 , 1 and 6
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
Cervical Cancer
An Intervention Study To Improve Human PapillomaVirus ( HPV) Immunization in Haitian and African American Girls
In the United States, Black women are more likely to die of cervical cancer than White women. In developing countries and globally, Haitian immigrant women are more likely to die of cervical cancer than any other women in the…
- Trial name
- HPV (NCT01254669)
- Testing
- BNI-brief Negotiated Interview
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Boston Medical Center
HPV Vaccinations
Improving HPV Vaccination Rates Among Rural and Native American Adolescents
This study will develop and implement a multi-level intervention aimed at improving human papillomavirus (HPV) vaccination rates at an Indian rural health clinic.
- Trial name
- NCT03801603
- Testing
- HPV vaccination training and education
- Where
- United States
- Volunteers
- 263 people, healthy volunteers welcome
- Sponsor
- University of California, Davis
Cervical Intraepithelial Neoplasia, Cervical Cancer
Long-term Effectiveness and Immuno-persistence Study of a Recombinant HPV 16/18 Bivalent Vaccine in Preadolescent Girls
The primary objective of this study is to evaluate the protective efficacy against future infections of HPV types 16/18 or related diseases and immuno-persistence (type specific IgG antibody) of the bivalent HPV vaccine in young…
- Conditions
- Cervical Intraepithelial Neoplasia, Cervical Cancer, Persistent Infection
- Trial name
- NCT06243666
- Testing
- Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli), No intervention
- Where
- China
- Volunteers
- 2,188 people, healthy volunteers welcome
- Sponsor
- Xiamen University
Human Papillomavirus Vaccines
Developing a Self-persuasion Intervention Promoting Adolescent HPV Vaccination: Feasibility Trial
HPV vaccine coverage among adolescents in the US is suboptimal. This is particularly true among traditionally underserved adolescents. Few parent-targeted interventions have focused on the parental decision-making process.
- Trial name
- NCT02535845
- Testing
- Project Voice, HPV Informational Video
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Infections, Papillomavirus
Safety and Immunogenicity of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) in Healthy Female Children 4-6 Years Old
The current study evaluates the immunogenicity and safety in 4-6 years old female subjects (experimental group) receiving Cervarix according to a 2-dose schedule (Month 0, 6), as compared to 4-6 years old female subjects (control…
- Trial name
- NCT01627561
- Testing
- Cervarix, Priorix, Infanrix
- Where
- 4 sites in Colombia, Mexico and 1 more
- Volunteers
- 148 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Immunization, Efficacy
GARDASIL 9: 3 Dose vs. 2 Dose With Delayed 3rd Dose
The investigators are evaluating whether 15-26 year old males and females need a 3rd dose of the human papillomavirus (HPV) vaccine, or whether 2 doses provide similar protection as 3 doses from the 9 types of HPV that it…
- Conditions
- Immunization, Efficacy, Human Papilloma Virus
- Trial name
- NCT03943875
- Testing
- 9-valent HPV vaccine, 2 dose efficacy, 9-valent HPV vaccine, 3 doses standard timing
- Where
- United States
- Volunteers
- 767 people, healthy volunteers welcome
- Sponsor
- The University of Texas Medical Branch, Galveston
HPV Vaccination Rates, HPV Vaccine Awareness
Effectiveness of Large Language Model-Based Chatbot Among Female University Stdents in Improving HPV Vaccine Awareness, Intention and Vaccination Rates
This is an interventional study targeting female university students. The primary objective of the study is to evaluate the effectiveness of a vaccine chatbot in improving HPV vaccination rates.
- Conditions
- HPV Vaccination Rates, HPV Vaccine Awareness, HPV Vaccination Intention
- Trial name
- NCT07351604
- Testing
- Scientific videos, Vaccine chatbot
- Volunteers
- 18,000 people, healthy volunteers welcome
- Sponsor
- Xiamen University
HPV Infections
Prevention of Human Papillomavirus (HPV) in 20 to 45 Year Old Chinese Women (V501-041)
A study to test the safety and effectiveness of Quadrivalent HPV (types 6, 11, 16, 18) L1 VLP vaccine against combined incidence of HPV 6/11/16/18-related persistent infection and vaccine type-specific genital disease among…
- Trial name
- NCT00834106
- Testing
- Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
- Volunteers
- 3,006 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Infections, Papillomavirus
Human Papillomavirus (HPV) Vaccine (Cervarix TM) Efficacy, Immunogenicity & Safety Trial in Adult Japanese Women With GSK Biologicals HPV-16/18 Vaccine
Infection with human papillomavirus (HPV) has been clearly established as the central cause of cervical cancer. Indeed, certain oncogenic types of HPV can infect the cervix (part of the uterus or womb).
- Trial name
- NCT00316693
- Testing
- HPV-16/18 vaccine (Cervarix™), Aimmugen™
- Where
- 4 sites in Japan
- Volunteers
- 1,046 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Human Papillomavirus Virus, HPV
Web App Technology for Boys and Parents: Improving HPV Vaccine Uptake
The uptake of vaccines for Human Papillomavirus (HPV) in the U.S. is far below recommended levels, particularly for adolescent boys and especially among minority families.
- Trial name
- NCT03000998
- Testing
- Web App Intervention Group, Usual Customary Care Group
- Where
- 3 sites in United States
- Volunteers
- 432 people, healthy volunteers welcome
- Sponsor
- Klein Buendel, Inc.
High Grade Cervical Intraepithelial Neoplasia
An Exploratory Safety and Immunogenicity Study of HPV16+ Immunotherapy VB10.16 in Women With HSIL; CIN 2/3)
This is an exploratory, open, prospective multi-centre study of VB10.16 immunotherapy in patients with high grade HPV16+ Cervical Intraepithelial Neoplasia (HSIL; CIN2/3).
- Trial name
- NCT02529930
- Testing
- VB10.16 Immunotherapy (DNA vaccine)
- Where
- 4 sites in Germany
- Volunteers
- 34 people
- Sponsor
- Nykode Therapeutics ASA
HPV Vaccines
Giving Immunizations Through Vaccine Education
This study will test the effectiveness of clinician-focused health IT-based decision support, family-focused health IT-based decision support, and a combination of both efforts, in increasing HPV and other adolescent vaccine…
- Trial name
- GIVE (NCT01159093)
- Testing
- Family Decision Support, Clinician Decision Support, Family Decision Support and Clinician Decision Support
- Where
- United States
- Volunteers
- 23,675 people
- Sponsor
- Children's Hospital of Philadelphia
HPV-16 +ve Oropharyngeal Carcinoma
Safety Study of Recombinant Listeria Monocytogenes(Lm)Based Vaccine Virus Vaccine to Treat Oropharyngeal Cancer
It is the investigators intention to investigate whether a specially designed vaccine, based on a genetically modified strain of the bacterium Listeria monocytogenes and called ADXS11-001 is safe to use and is able to boost the…
- Trial name
- REALISTIC: (NCT01598792)
- Testing
- ADXS11-001
- Where
- 4 sites in United Kingdom
- Volunteers
- 2 people
- Sponsor
- University of Liverpool
Meningococcal Meningitis
A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When Administered With MenACWY in Adolescents
The main objective is to determine whether immune responses to Tdap (GlaxoSmithKline, Boostrix®) and HPV vaccine (Merck \& Co., Inc., Gardasil®) when administered concomitantly with MenACWY are comparable to responses elicited by…
- Trial name
- NCT01424644
- Testing
- MenACWY-CRM Conjugate Vaccine + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine
- Where
- 20 sites in United States, Italy
- Volunteers
- 801 people, healthy volunteers welcome
- Sponsor
- Novartis
Penile Cancer, Anal Cancer
Evaluate the Safety and Immunogenicity of a 9-valent HPV Vaccine in Chinese Healthy Male Aged 9-45 Year-old
To evaluate the safety and tolerability of the 9vHPV vaccine in Chinese healthy male aged 9 to 45 years.
- Conditions
- Penile Cancer, Anal Cancer, PIN-1, PIN-2
- Trial name
- NCT05518201
- Where
- China
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.